Embecta Corp. (EMBC)

Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume declines, and higher R&D expenses, despite improved margins and debt reduction. The dividend yield of 4.77% may appeal to income investors, but near-term growth prospects remain limited, warranting a Hold rating.

The S&P 600 Small/MidCap index offers high-yield dividend opportunities, with 33 out of 53 top-yielding stocks meeting both the 'safer' and IDEAL dividend Dogcatcher criteria. Top ten S&P600 dividend 'dogs' are projected to deliver 24% to 93% net gains by November 2026, based on analyst targets and current yields. Stocks like KNTK, SM, CRGY, and DEI stand out for strong total return potential, but investors should beware of negative free cash flow in some high-yield picks.

Embecta Corp. ( EMBC ) Q4 2025 Earnings Call November 25, 2025 8:00 AM EST Company Participants Pravesh Khandelwal - VP & Head of Investor Relations Devdatt Kurdikar - President, CEO & Director Jake Elguicze - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Michael Polark - Wolfe Research, LLC Anthony Petrone - Mizuho Securities USA LLC, Research Division Gracia Mahoney - BofA Securities, Research Division Presentation Operator Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will be available on the company's website following the call.

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025.

PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2025.

AXQ Capital LP acquired a new stake in Embecta Corp. (NASDAQ: EMBC) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor acquired 31,298 shares of the company's stock, valued at approximately $303,000. AXQ Capital LP owned 0.05% of Embecta at the end of the most recent

Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.

PARSIPPANY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that David J.

PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today announced a significant expansion of its partnership with Direct Relief, the leading humanitarian aid organization and largest charitable insulin provider in the United States.

PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2025 financial results and provide an operational update, including preliminary fiscal year 2026 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 25, 2025.

ELAN, DINO and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 6, 2025.

JXN, EMBC and KT made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 9, 2025.

Embecta's restructuring and discontinuation of the patch pump system have significantly improved profitability, enabling substantial cost savings and debt reduction. The company is refocusing on core strengths, expanding into drug delivery and chronic care, and leveraging new pharma partnerships for broader growth. Financial guidance shows strong adjusted EPS and EBITDA margin growth, with cost-cutting driving earnings gains despite modest revenue declines.

EMBC's strong Q3 results and improved profitability highlight management's effective cost controls, despite revenue growth being driven by one-off events. The new strategic direction focuses on strengthening the core insulin delivery business and expanding into adjacent markets while aggressively deleveraging. Short-term revenue headwinds persist due to a shrinking core market, but EMBC's reputation and distribution network position it well for future adjacent market growth.

PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:

The consensus price target hints at a 25.7% upside potential for Embecta Corp. (EMBC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.